Join Drs Nihar Desai and Erica Spatz as they discuss the critical importance of social determinants of health in preventing and managing cardiorenal conditions.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999840. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/38103820/

What Is a Social Determinant of Health? Back to Basics https://pubmed.ncbi.nlm.nih.gov/34162174/

Multi-Ethnic Study of Atherosclerosis (MESA): JACC Focus Seminar 5/8 https://pubmed.ncbi.nlm.nih.gov/34167645/

What to Know About PREVENT, the AHA's New Cardiovascular Disease Risk Calculator https://pubmed.ncbi.nlm.nih.gov/38150239/

Accountable Health Communities Model https://www.cms.gov/priorities/innovation/innovation-models/ahcm

Racial and Ethnic Approaches to Community Health (REACH) https://www.cdc.gov/reach/php/about/index.html

Join Drs Nihar Desai and Chiadi Ndumele as they define and discuss cardiorenal metabolic syndrome, a chronic health condition with the potential to impact up to 90% of the US population.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999839. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807924/

American Heart Association PREVENTTM Online Calculator https://professional.heart.org/en/guidelines-and-statements/prevent-calculator

Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020 https://pubmed.ncbi.nlm.nih.gov/38717747/

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/24222018/

Renoprotection With SGLT2 Inhibitors in Type 2 Diabetes Over a Spectrum of Cardiovascular and Renal Risk https://pubmed.ncbi.nlm.nih.gov/33222693/

Cardiovascular and Kidney Outcomes With Finerenone in Patients With Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis https://pubmed.ncbi.nlm.nih.gov/35023547/

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) https://classic.clinicaltrials.gov/ct2/show/NCT04435626

Novo Nordisk Will Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166327

Long-Term Kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease in the SELECT Trial https://pubmed.ncbi.nlm.nih.gov/38796653/